Pneumology - Original Articles Open access

Evaluation of the efficacy of convalescent plasma in moderate to severe COVID-19 during 2020-2021: a retrospective observational study

Authors

Published
20 December 2024
Section
Pneumology - Original Articles

Abstract

Convalescent plasma therapy (CPT) is one of the treatment modalities used for COVID-19. Initial smaller studies showed the usefulness of CPT in COVID-19, but larger studies showed that it is not effective. This is a retrospective observational study conducted between 1st June 2020 and 31st July 2021 at a tertiary hospital in Noida, India. Our analysis was done on 213 COVID-19 patients, comprising 170 cases who were given convalescent plasma and 43 controls who did not get CPT. Outcomes analyzed were improvement in PaO2:FiO2 ratio (PFR) by day 5 of CPT, 28-day mortality, and level of inflammatory markers. Mean PFR before plasma transfusion was comparable between CPT and control groups (142.11±73.99 vs. 151.11±88.87, p=0.56). There was no significant difference in mean PFR after 5 days of CPT between cases and the control group (187.02±102.34 vs. 160.29±83.39, p=0.206). 28-day mortality was 47.05% in the CPT group and 37.20% in the control group (p=0.246). Mortality among the subgroup of patients on invasive mechanical ventilation was 89.74% in cases and 80% in controls (p=0.518). No significant difference was found in levels of serum ferritin, interleukin-6, and C-reactive protein between the two groups. Convalescent plasma does not have a significant effect on day 5 PFR and 28-day mortality. Our study could not find any subgroup of patients who would benefit from CPT. This study reinforces that CPT does not benefit moderate to severe patients with COVID-19.

Ethics Approval

The study protocol was approved by the Fortis Hospital Institutional Ethics Committee meeting, held on 6th October 2022, document number- FHIEC/2022/06.

References

  1. Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe covid-19 in older adults. N Engl J Med 2021;384:610-8. DOI: https://doi.org/10.1056/NEJMc2104747
  2. Salazar E, Christensen PA, Graviss EA, et al. Significantly decreased mortality in a large cohort of coronavirus disease 2019 [COVID-19] patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome coronavirus 2 [SARS-COV-2] spike protein IgG. Am J Pathol 2021;191:90-107. DOI: https://doi.org/10.1016/j.ajpath.2020.10.008
  3. Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med 2021;384:1015-27. DOI: https://doi.org/10.1056/NEJMoa2031893
  4. Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020;371:m3939. DOI: https://doi.org/10.1136/bmj.m3939
  5. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 2021;397:2049-59. DOI: https://doi.org/10.1016/S0140-6736(21)00897-7
  6. Bégin P, Callum J, Jamula E, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med 2021;27:2012-24. DOI: https://doi.org/10.1038/s41591-021-01488-2
  7. Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020;130:2757-65. DOI: https://doi.org/10.1172/JCI138745
  8. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015;211:80-90. DOI: https://doi.org/10.1093/infdis/jiu396
  9. ICMR. Evidence based advisory to address inappropriate use of convalescent plasma in covid-19 patients. Available from: https://drugscontrol.org/pdf/ICMR_ADVISORY_Convalescent_plasma_17112020.pdf.
  10. Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020;324:460-70. DOI: https://doi.org/10.1001/jama.2020.12607
  11. Gharbharan A, Jordans CCE, Geurtsvan Kessel C, et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Commun 2021;12:3189. DOI: https://doi.org/10.1038/s41467-021-23469-2
  12. Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med 2021;384:619-29. DOI: https://doi.org/10.1056/NEJMoa2031304
  13. Piechotta V, Chai KL, Valk SJ, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 2020;7:CD013600. DOI: https://doi.org/10.1002/14651858.CD013600.pub2
  14. Kurtz P, Righy C, Gadelha M, et al. Effect of convalescent plasma in critically ill patients with COVID-19: An observational study. Front Med 2021;8:630982. DOI: https://doi.org/10.3389/fmed.2021.630982
  15. ICMR. e-Samvaad May 2021.
  16. Government of India. Final G.S.R. 166(E)_Amendment in Part X B & Part XII B pertains to blood center and blood components, drugs and cosmetics act 1940 and rules 1945, amended 11th march 2020. Available from: https://drugscontrol.py.gov.in/sites/default/files/GSR-166-E.pdf.
  17. AJ Padkin, WJ Kinnear. Supplemental oxygen and nasal intermittent positive pressure ventilation. Eur Respir J 1996;9:834-36. DOI: https://doi.org/10.1183/09031936.96.09040834
  18. Conte G, Cei M, Evangelista I, et al. The meaning of D-dimer value in Covid-19. Clin Appl Thromb Hemost 2021;27:10760296211017668. DOI: https://doi.org/10.1177/10760296211017668
  19. Artifoni M, Danic G, Gautier G, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis 2020;50:211-6. DOI: https://doi.org/10.1007/s11239-020-02146-z
  20. Duan K, Liu B, Li C, et al., Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020;117:9490-6. DOI: https://doi.org/10.1073/pnas.2006961117
  21. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323:1582-9. DOI: https://doi.org/10.1001/jama.2020.4783
  22. Hartman WR, Hess AS, Connor JP. Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest, Transl Med Commun 2020;5:17. DOI: https://doi.org/10.1186/s41231-020-00068-9
  23. WHO. Therapeutics and COVID-19. 2021. Available from: https://www.who.int/docs/default-source/coronaviruse/2021.4-lg-therapeutics-and-covid-19-2021-12-07-en.pdf.
  24. Budhiraja S, Dewan A, Ritesh Aggarwal, et al. Effectiveness of convalescent plasma in Indian patients with COVID-19. Blood Cells Mol Dis 2021;88:102548. DOI: https://doi.org/10.1016/j.bcmd.2021.102548
  25. Camou F, Tinevez C, Mathilde Beguet-Yachine, et al. Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia. J Med Virol 2021;93:5594-8. DOI: https://doi.org/10.1002/jmv.27032
  26. Pouladzadeh M, Safdarian M, Eshghi P, et al. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. Intern Emerg Med 2021;16:2181-91. DOI: https://doi.org/10.1007/s11739-021-02734-8
  27. Zietz M, Zucker J, Tatonetti NP. Associations between blood type and COVID-19 infection, intubation, and death. Nat Commun 2020;11:5761. DOI: https://doi.org/10.1038/s41467-020-19623-x
  28. Agrawal A, Jha T, Gogoi P, et al. Effect of convalescent plasma therapy on mortality in moderate-to-severely Ill COVID-19 patients. Transfus Apher Sci 2022;61:103455. DOI: https://doi.org/10.1016/j.transci.2022.103455
  29. Altuntas F, Ata N, Tugce Nur Yigenoglu, et al. Convalescent plasma therapy in patients with COVID-19. Transfus Apher Sci 2021;60:102955. DOI: https://doi.org/10.1016/j.transci.2020.102955
  30. Kournoutou GG, Dinos G. Azithromycin through the Lens of the COVID-19 treatment. Antibiotics 2022;11:1063. DOI: https://doi.org/10.3390/antibiotics11081063
  31. Hennekens CH, Rane M, Solano J, et al. Updates on hydroxychloroquine in prevention and treatment of COVID-19. Am J Med 2022;135:7-9. DOI: https://doi.org/10.1016/j.amjmed.2021.07.035
  32. Jabaley CS, Coopersmith CM. Vitamin C for patients with COVID-19: more evidence of lack of efficacy in patients with sepsis. JAMA 2023;330:1739-41. DOI: https://doi.org/10.1001/jama.2023.18592
  33. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384:693-704. DOI: https://doi.org/10.1056/NEJMoa2021436

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.